2. Academic Validation
  3. TAK1 inhibition in the DFG-out conformation

TAK1 inhibition in the DFG-out conformation

  • Chem Biol Drug Des. 2013 Nov;82(5):500-5. doi: 10.1111/cbdd.12169.
Iain Kilty 1,  Martin P Green,  Andrew S Bell,  David G Brown,  Peter G Dodd,  Christopher Hewson,  Samantha J Hughes,  Christopher Phillips,  Thomas Ryckmans,  Robert T Smith,  Willem P van Hoorn,  Philip Cohen,  Lyn H Jones
Affiliations

Affiliation

  • 1 Pfizer World Wide Research and Development, Ramsgate Road, Sandwich, CT13 9NJ, UK; BioTherapeutics Research and Development, Pfizer, Cambridge, MA, 02140, USA.
PMID: 23745990 DOI: 10.1111/cbdd.12169
Abstract

The first example of an inhibitor of the kinase TAK1 that binds in the DFG-out conformation is disclosed. These preliminary studies used kinase-targeted screening and structure-based drug design to create a molecule with dual pharmacological inhibition of p38 and TAK1 that demonstrated significant activity in a cell-based, anti-inflammatory assay.

Keywords

X-ray crystallography; chemical biology; drug design; kinase; phosphatase; structure-based drug design.

Figures
Products